BillionToOne Inc.

3 days ago · seekingalpha.com

BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. BLLN's Unity Complete offers unmatched prenatal screening convenience and accuracy, bypassing paternal testing and expanding to 130 genes, outpacing competitors like Natera. Oncology testing is accelerating (176% y/y growth), with Northstar Response's Medicare coverage decision by end-2026 as a key catalyst.

4 days ago · zacks.com

BillionToOne (BLLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 days ago · globenewswire.com

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company will participate in two upcoming investor conferences.

19 days ago · globenewswire.com

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

20 days ago · seekingalpha.com

BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects the capabilities of its unique QCT technology that underpins its oncology and prenatal diagnostics product suite. BLLN trades at a slight EV/sales discount to peers but offers best-in-class forward topline growth of 38% p.a., far outpacing the industry average of 22%.

26 days ago · globenewswire.com

Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response

1 month ago · fool.com

The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.

2 months ago · fool.com

The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider's directly-held equity stake, and a portion belonging to his spouse.

2 months ago · prnewswire.com

MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.

2 months ago · prnewswire.com

New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals.